{"id":"movantik-naloxegol","safety":{"commonSideEffects":[{"rate":"21","effect":"Abdominal pain"},{"rate":"19","effect":"Diarrhea"},{"rate":"8","effect":"Nausea"},{"rate":"9","effect":"Headache"},{"rate":"6","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxegol is a pegylated derivative of naloxone designed to be a selective peripheral mu-opioid receptor antagonist. By antagonizing opioid receptors locally in the GI tract while minimizing systemic exposure and central nervous system penetration, it counteracts the constipating effects of opioid medications without reducing their analgesic efficacy or precipitating withdrawal.","oneSentence":"Naloxegol is a peripheral mu-opioid receptor antagonist that blocks opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:59.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid-induced constipation in adult patients with chronic non-cancer pain"}]},"trialDetails":[{"nctId":"NCT02946580","phase":"PHASE4","title":"Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Constipation","enrollment":53},{"nctId":"NCT02998606","phase":"PHASE2","title":"Movantik for Opioid-Related Esophageal Disorders","status":"TERMINATED","sponsor":"Temple University","startDate":"2017-01","conditions":"Opioid-Induced Disorders, Esophagus Disorder","enrollment":2},{"nctId":"NCT03060512","phase":"PHASE4","title":"To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-02","conditions":"Opioid Induced Constipation","enrollment":276}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":161,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MOVANTIK™ (naloxegol)","genericName":"MOVANTIK™ (naloxegol)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxegol is a pegylated derivative of naloxone that blocks opioid receptors in the gastrointestinal tract to reverse opioid-induced constipation while minimizing systemic opioid antagonism. Used for Opioid-induced constipation in adult patients with chronic non-cancer pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}